跳至主要内容
临床试验/EUCTR2014-005070-11-PL
EUCTR2014-005070-11-PL进行中(未招募)1 期

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

AbbVie Deutschland GmbH & Co. KG0 个研究点目标入组 1,100 人开始时间: 2015年10月5日最近更新:
适应症

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
1,100

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
Female

入选标准

  • Subject must be = 18 years of age
  • High-grade serous adenocarcinoma
  • Willing to undergo testing for gBRCA
  • Eastern Cooperative Oncology Group performance status of 0, 1, or 2
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) no
  • F.1.2.1 Number of subjects for this age range 990
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range 110

排除标准

  • Following histologic cell types are ineligible: endometrioid adenocarcinoma, carcinosarcoma, undifferentiated carcinoma, mixed epithelial adenocarcinoma, adenocarcinoma not otherwise specified, mucinous adenocarcinoma, clear cell adenocarcinoma, low-grade serous adenocarcinoma, or malignant Brenner's tumor.
  • Synchronous primary endometrial cancer, or a past history of endometrial cancer.
  • Prior radiotherapy to any portion of the abdominal cavity or pelvis
  • Clinically significant uncontrolled condition(s), including but not limited to: Bowel obstruction or gastric outlet obstruction.
  • History or evidence upon physical examination of central nervous system (CNS) disease.

研究者

相似试验